These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 32084455)

  • 21. Risks of peri- and postoperative complications with glucagon-like peptide-1 receptor agonists.
    Klonoff DC; Kim SH; Galindo RJ; Joseph JI; Garrett V; Gombar S; Aaron RE; Tian T; Kerr D
    Diabetes Obes Metab; 2024 Aug; 26(8):3128-3136. PubMed ID: 38742898
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of SGLT2 inhibitors and GLP1 receptor agonists on arterial stiffness: A meta-analysis of randomized controlled trials.
    Rizos EC; Tagkas CF; Asimakopoulos AI; Tsimihodimos V; Anastasiou G; Rizzo M; Agouridis AP; Ntzani EE
    J Diabetes Complications; 2024 Jul; 38(7):108781. PubMed ID: 38833853
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis.
    Potts JE; Gray LJ; Brady EM; Khunti K; Davies MJ; Bodicoat DH
    PLoS One; 2015; 10(6):e0126769. PubMed ID: 26121478
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glucagon-like peptide-1 receptor agonists and pancreatic cancer: a meta-analysis with trial sequential analysis.
    Pinto LC; Falcetta MR; Rados DV; Leitão CB; Gross JL
    Sci Rep; 2019 Feb; 9(1):2375. PubMed ID: 30787365
    [TBL] [Abstract][Full Text] [Related]  

  • 25. GLP-1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials.
    Cao C; Yang S; Zhou Z
    Endocrine; 2019 Nov; 66(2):157-165. PubMed ID: 31420784
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bone fracture risk is not associated with the use of glucagon-like peptide-1 receptor agonists: a population-based cohort analysis.
    Driessen JH; Henry RM; van Onzenoort HA; Lalmohamed A; Burden AM; Prieto-Alhambra D; Neef C; Leufkens HG; de Vries F
    Calcif Tissue Int; 2015 Aug; 97(2):104-12. PubMed ID: 25894068
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glucagon-like peptide-1 receptor agonist (GLP1-RA) therapy in type 2 diabetes.
    Ng E; Shaw JE; Wood A; Maple-Brown LJ; Hare MJ
    Aust J Gen Pract; 2022 Jul; 51(7):513-518. PubMed ID: 35773162
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Updated Meta-Analysis of Cardiovascular Outcome Trials Evaluating Cardiovascular Efficacy of Glucagon-Like Peptide-1 Receptor Agonists.
    Patoulias D; Papadopoulos C; Kassimis G; Karagiannis A; Doumas M
    Am J Cardiol; 2021 Nov; 159():143-146. PubMed ID: 34497008
    [No Abstract]   [Full Text] [Related]  

  • 29. Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rate.
    Sardu C; Paolisso P; Sacra C; Santamaria M; de Lucia C; Ruocco A; Mauro C; Paolisso G; Rizzo MR; Barbieri M; Marfella R
    Cardiovasc Diabetol; 2018 Oct; 17(1):137. PubMed ID: 30348145
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Impact of glucagon-like peptide-1 receptor agonists on nasopharyngitis and upper respiratory tract infection among patients with type 2 diabetes: a network meta-analysis].
    Li ZX; Wu SS; Yang ZR; Zhan SY; Sun F
    Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Jun; 48(3):454-9. PubMed ID: 27318907
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glucagon-like peptide-1 receptor agonists and microvascular outcomes in type 2 diabetes: A systematic review and meta-analysis.
    Avgerinos I; Karagiannis T; Malandris K; Liakos A; Mainou M; Bekiari E; Matthews DR; Tsapas A
    Diabetes Obes Metab; 2019 Jan; 21(1):188-193. PubMed ID: 30058208
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Meta-Analysis of Randomized Controlled Trials Evaluating the Effect of Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Receptor Agonists on Blood Pressure Levels in Patients With Type 2 Diabetes Mellitus.
    Patoulias D; Michailidis T; Papadopoulos C; Karagiannis A; Doumas M
    Am J Cardiol; 2022 Mar; 166():144-145. PubMed ID: 34974899
    [No Abstract]   [Full Text] [Related]  

  • 33. The cardiovascular effects of glucagon-like peptide-1 receptor agonists: a trial sequential analysis of randomized controlled trials.
    Wu S; Sun F; Zhang Y; Yang Z; Hong T; Chen Y; Zhan S
    J Clin Pharm Ther; 2014 Feb; 39(1):7-13. PubMed ID: 24127768
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glucagon-like peptide-1 receptor agonists and mental health: A meta-analysis of randomized controlled trials.
    Silverii GA; Marinelli C; Mannucci E; Rotella F
    Diabetes Obes Metab; 2024 Jun; 26(6):2505-2508. PubMed ID: 38449004
    [No Abstract]   [Full Text] [Related]  

  • 35. Effect of glucagon-like peptide-1 receptor agonists on circulating levels of leptin and resistin: A meta-analysis of randomized controlled trials.
    Simental-Mendía LE; Sánchez-García A; Linden-Torres E; Simental-Mendía M
    Diabetes Res Clin Pract; 2021 Jul; 177():108899. PubMed ID: 34098057
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glucagon-Like Peptide-1 Receptor Agonists and Prevention of Stroke Systematic Review of Cardiovascular Outcome Trials With Meta-Analysis.
    Bellastella G; Maiorino MI; Longo M; Scappaticcio L; Chiodini P; Esposito K; Giugliano D
    Stroke; 2020 Feb; 51(2):666-669. PubMed ID: 31813360
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glucagon-like peptide-1 receptor agonists and cardiovascular disease: from LEADER to EXSCEL.
    Torekov SS
    Cardiovasc Res; 2018 Aug; 114(10):e70-e71. PubMed ID: 30052921
    [No Abstract]   [Full Text] [Related]  

  • 38. Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials.
    Mabilleau G; Mieczkowska A; Chappard D
    J Diabetes; 2014 May; 6(3):260-6. PubMed ID: 24164867
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
    Li Y; Rosenblit PD
    Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glucagon-like peptide-1 receptor agonists and atrial fibrillation: a systematic review and meta-analysis of randomised controlled trials.
    Monami M; Nreu B; Scatena A; Giannini S; Andreozzi F; Sesti G; Mannucci E
    J Endocrinol Invest; 2017 Nov; 40(11):1251-1258. PubMed ID: 28569363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.